Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Long-Term Safety of Azathioprine Therapy in Multiple Sclerosis
Neurol 43:831-833, Amato,M.P.,et al, 1993
Taste & Smell in Disease (First of Two Parts)
NEJM 308:1275-1279, Schiffman,S.S., 1983
Upbeat Nystagmus
JAMA 225:312, Daroff,R.B.,et al, 1973
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Clomipramine Induced Neuroleptic Malignant Syndrome and Pyrexia of Unknown Origin
BMJ 329:1333-1335, Haddow,A.M.,et al, 2004
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998
Opsoclonus
Semin Neurol 16:21-26, Averbuch-Heller,L.&Remler,B., 1996
Nocturnal Blood Pressure Dip in Stroke Survivors, A Pilot Study
Stroke 26:1373-1378, Nakamura,K.,et al, 1995
Reversible Neurologic Toxicity with Fludarabine Phosphate for Mycosis Fungiodes & Chronic Lymphocytic Leukemia
Ann Int Med 118:114-116, Cohen,R.B.,et al, 1993
Neuroleptic-Induced Catatonia as a Stage in the Progression Toward NMS
J Am Acad Child Adolesc Psychiatry 31:1161-1164, Woodbury,M.M.&Woodbury,M.A., 1992
Putaminal Hemorrhage:Clinical-Computed Tomographic Correlations
Neuroradiology 32:200-206, Weisberg,L.A.,et al, 1990
Adverse Drug Effects Attributed to Phenylpropanolamine:A Review of 142 Case Reports
Am J Med 89:195-208, Lake,C.R.,et al, 1990
Phenobarbital Rheumatism in Patients with Brain Tumor
Ann Neurol 25:92-94, Taylor,L.P.&Posner,J.B., 1989
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Azathioprine Toxicity During Long-Term Immunosuppression of Generalized Myasthenia Gravis
Neurol 38:258-261, Hohlfeld,R.,et al, 1988
Intracerebral Hemorrhage & Phenylpropanolamine Use
Neurol 37:399-404, Kase,C.S.,et al, 1987
Pimozide Treatment of Tic & Tourette Disorders
Pediatrics 79:1032-1039, Shapiro,A.K.,et al, 1987
Opsoclonus in Adults
Arch Neurol 43:1165-1175, Digre,K.B., 1986
Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
The Neuroleptic Malignant Syndrome
Arch Int Med 142:1183-1185, Smego,R.A.,et al, 1982
Neuroleptic Malignant Syndrome
Arch Neurol 37:462-463, Morris,H.H.,et al, 1980